US tariff policy uncertainty on pharma products
While current tariffs exempt pharma, potential changes under Section 232 could impact API exports; management noted contracts are largely FOB but impact unclear.
AARTIPHARM / Q1-FY26 / risks
Keep the risk register visible.
Aarti Pharmalabs · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Lumpy CDMO revenue recognition
CDMO revenue is back-end loaded and lumpy due to multi-stage manufacturing; Q1 performance may not be indicative of full-year trajectory.
Ganesh Polychem joint venture ramp-up risk
GPL plant underwent shutdown for modifications; restart in July may delay contribution to profitability in FY26.
Capacity utilization drag from new greenfield plant
Atali greenfield plant will have higher opex initially; full utilization may take until end of FY26, pressuring near-term margins.